CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM steps into Therapeutic Area on a large-scale

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the Therapeutic Area Ophthalmology (AMD – age-related macular degeneration) on a global level.

VISUDYNE®, with its Active Ingredient Verteporfin, is used to treat patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

CHEPLAPHARM is offering its branded products worldwide. VISUDYNE®, an established branded niche product with continuous significance in the therapy of AMD, scores with its Unique Selling Proposition (USP) and a stable market position. Furthermore, the product contribues actively to our ambitious growth strategy by reinforcing CHEPLAPHARM’s International Footprint especially in selected Asian and European countries. Consequently, this acquisition is another step in pursuing our vision to strengthen our position as a global player.

Therefore, we are very excited about having reached an agreement with Novartis Pharma AG about the acquisition of VISUDYNE® - a product that is bringing further scale and diversity to our existing product portfolio.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)

Investor Relations topics

Back to top expand_less